Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea

Journal of the American Academy of Dermatology

Volumn 56, Issue 5, 2007, Pages 791-802

  Del Rosso, James Q ^a   Webster, Guy F ^b   Jackson, Mark ^c   Rendon, Marta ^d   Rich, Phoebe ^e   Torok, Helen ^f   Bradshaw, Mark ^g  

^a TOURO UNIVERSITY NEVADA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c University of Louisville School of Medicine   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f Trillium Creek Dermatology and Surgery Center   (Saudi Arabia)

^g Global Consulting Partners in Medical Biometrics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; PLACEBO;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EVALUATION; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INFLUENZA; MALE; MULTICENTER STUDY; MYCOSIS; NAUSEA; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; ROSACEA; SIDE EFFECT; SINUSITIS; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; DOUBLE-BLIND METHOD; DOXYCYCLINE; FEMALE; HUMANS; MALE; MIDDLE AGED; ROSACEA; TREATMENT OUTCOME;

EID: 34147119086     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.11.021     Document Type: Article

References (51)

1. Powell F.C. Clinical practice. Rosacea. N Engl J Med 352 (2005) 793-803
2. Berg M., and Liden S. An epidemiological study of rosacea. Acta Derm Venereol 69 (1989) 419-423
3. Dahl M.V. Pathogenesis of rosacea. Adv Dermatol 17 (2001) 29-45
4. Bamford J.T. Rosacea: current thoughts on origin. Semin Cutan Med Surg 20 (2001) 199-206
5. Crawford G.H., Pelle M.T., and James W.D. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 51 (2004) 327-341 quiz 42-4
6. Del Rosso J.Q. Medical management of rosacea with topical agents: a thorough appraisal of available treatment options and recent advances. Cosmet Dermatol 16 (2003) 47-60
7. Aroni K., Tsagroni E., Lazaris A.C., Patsouris E., and Agapitos E. Rosacea: a clinicopathological approach. Dermatology 209 (2004) 177-182
8. Wilkin J., Dahl M., Detmar M., Drake L., Feinstein A., Odom R., et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 46 (2002) 584-587
9. Wilkin J., Dahl M., Detmar M., Drake L., Liang M.H., Odom R., et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol 50 (2004) 907-912
10. Del Rosso J.Q. Medical treatment of rosacea with emphasis on topical therapies. Expert Opin Pharmacother 5 (2004) 5-13
11. Wilkin J.K. Rosacea. Pathophysiology and treatment. Arch Dermatol 130 (1994) 359-362
12. Pelle M.T., Crawford G.H., and James W.D. Rosacea: II. Therapy. J Am Acad Dermatol 51 (2004) 499-512 quiz 3-4
13. Bikowski J.B., and Goldman M.P. Rosacea: where are we now?. J Drugs Dermatol 3 (2004) 251-261
14. Vibramycin. [package insert] (2003), Pfizer Labs
15. Oracea. [package insert] (2006), CollaGenex Pharmaceuticals, Inc
16. Lehmann E.L. Nonparametrics: statistical methods based on ranks (1975), Holden-Day, San Francisco pp. 132-7, 145
17. van Elteren P.H. On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat Inst 37 (1960) 351-361
18. Agresti A. Categorical data analysis. 2nd ed. (2002), Wiley, New York
19. Agresti A. Analysis of ordinal categorical data (1984), Wiley, New York
20. Brown E.G. Using MedDRA. Implications for risk management. Drug Saf 27 (2004) 591-602
21. MetroGel 1%. [package insert] (2005), Galderma Laboratories, Inc, Fort Worth (TX)
22. Thiboutot D., Thieroff-Ekerdt R., and Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol 48 (2003) 836-845
23. Wilkin J.K. Oral thermal-induced flushing in erythematotelangiectatic rosacea. J Invest Dermatol 76 (1981) 15-18
24. Sobye P. Aetiology and pathogenesis of rosacea. Acta Derm Venereol 30 (1950) 137-153
25. Neumann E., and Frithz A. Capillaropathy and capillaroneogenesis in the pathogenesis of rosacea. Int J Dermatol 37 (1998) 263-266
26. Helm K.F., Menz J., Gibson L.E., and Dicken C.H. A clinical and histopathologic study of granulomatous rosacea. J Am Acad Dermatol 25 (1991) 1038-1043
27. Schmidt N., and Gans E. Demodex and rosacea, I: the prevalence and numbers of Demodex mites in rosacea. Cosmet Dermatol 17 (2004) 497-502
28. Schmidt N., and Gans E. Demodex and rosacea, II: Demodex mites and rosacea inflammation. Cosmet Dermatol 17 (2004) 575-580
29. Forton F., Germaux M.A., Brasseur T., De Liever A., Laporte M., Mathys C., et al. Demodicosis and rosacea: epidemiology and significance in daily dermatologic practice. J Am Acad Dermatol 52 (2005) 74-87
30. Dahl M.V., Ross A.J., and Schlievert P.M. Temperature regulates bacterial protein production: possible role in rosacea. J Am Acad Dermatol 50 (2004) 266-272
31. Dirschka T., Tronnier H., and Folster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol 150 (2004) 1136-1141
32. Oztas M.O., Balk M., Ogus E., Bozkurt M., Ogus I.H., and Ozer N. The role of free oxygen radicals in the aetiopathogenesis of rosacea. Clin Exp Dermatol 28 (2003) 188-192
33. Miyachi Y. Potential antioxidant mechanism of action for metronidazole: implications for rosacea management. Adv Ther 18 (2001) 237-243
34. Miyachi Y., Yoshioka A., Imamura S., and Niwa Y. Effect of antibiotics on the generation of reactive oxygen species. J Invest Dermatol 86 (1986) 449-453
35. Jones D. Reactive oxygen species and rosacea. Cutis 74 (2004) 17-20 32-4
36. Golub L.M., Lee H.M., Ryan M.E., Giannobile W.V., Payne J., and Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 12 (1998) 12-26
37. Jain A., Sangal L., Basal E., Kaushal G.P., and Agarwal S.K. Anti-inflammatory effects of erythromycin and tetracycline on Propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils. Dermatol Online J 8 (2002) 2
38. Akamatsu H., Asada M., Komura J., Asada Y., and Niwa Y. Effect of doxycycline on the generation of reactive oxygen species: a possible mechanism of action of acne therapy with doxycycline. Acta Derm Venereol 72 (1992) 178-179
39. Murphy G. Ultraviolet light and rosacea. Cutis 74 (2004) 13-16 32-4
40. Bonamigo R.R., Bakos L., Edelweiss M., and Cartell A. Could matrix metalloproteinase-9 be a link between Demodex folliculorum and rosacea?. J Eur Acad Dermatol Venereol 19 (2005) 646-647
41. Alfonso A., Sobrin L., and Monroy D. Tear fluid gelatinase B activity correlates with IL-1 alpha concentration and fluorescein clearance in ocular rosacea. Invest Ophthalmol Vis Sci 40 (1999) 2506-2512
42. Webster G.F., Toso S.M., and Hegemann L. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C. Arch Dermatol 130 (1994) 748-752
43. Amin A.R., Attur M.G., Thakker G.D., Patel P.D., Vyas P.R., Patel R.N., et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A 93 (1996) 14014-14019
44. Fowler J. Combined effect of anti-inflammatory dose doxycycline and metronidazole topical gel 1% in the treatment of rosacea. Poster P128 presented at: 65th Annual American Academy of Dermatology Meeting; February 2-6, 2006; Washington, DC.
45. Bikowski J.B. Subantimicrobial dose doxycycline for acne and rosacea. SkinMed 2 (2003) 234-245
46. Skidmore R., Kovach R., Walker C., Thomas J., Bradshaw M., Leyden J., et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 139 (2003) 459-464
47. Weinberg J.M. The anti-inflammatory effects of tetracyclines. Cutis 75 Suppl 4 (2005) 6-11
48. Berman B., and Zell D. Subantimicrobial dose doxycycline: a unique treatment for rosacea. Cutis 75 Suppl 4 (2005) 19-24
49. Osterberg L., and Blaschke T. Adherence to medication. N Engl J Med 353 (2005) 487-497
50. Claxton A.J., Cramer J., and Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23 (2001) 1296-1310
51. Walker C, Webster GF. A multicenter, double-blind, randomized trial to evaluate the long-term safety of anti-inflammatory dose doxycycline. Poster presented at: Fall Clinical Dermatology Conference, The Foundation for Research and Education in Dermatology; October 6-9, 2006; Las Vegas, Nev.